Comparative Pharmacology
Head-to-head clinical analysis: AZMIRO versus DEPAKOTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZMIRO versus DEPAKOTE.
AZMIRO vs DEPAKOTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azmiro is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in target tissues, thereby modulating estrogenic effects.
Increases GABA levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase; also blocks voltage-gated sodium channels and T-type calcium channels.
Administer 600 mg intravenously over 60 minutes every 8 hours for 7-14 days.
Initial dose 750 mg/day PO in divided doses; increase by 250-500 mg/day every 3-7 days; maintenance dose 1000-2000 mg/day PO divided BID or TID; maximum 60 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life: 4.5 hours (range 3–6 h); supports twice-daily dosing.
Terminal: 9-16 hours (mean 12 h); extended with hepatic dysfunction, co-administered enzyme inhibitors, or in elderly.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Renal: <3% as unchanged drug; >95% as metabolites (glucuronide conjugates, oxidation products). Biliary/fecal: minor, <5%.
Category C
Category C
Anticonvulsant
Anticonvulsant